WuXi Biologics (Cayman) Inc. (HKG:2269)

WuXi Biologics Revenue

WuXi Biologics had revenue of 9.95B CNY in the half year ending June 30, 2025, with 17.21% growth. This brings the company's revenue in the last twelve months to 20.05B, up 17.16% year-over-year. In the year 2024, WuXi Biologics had annual revenue of 18.68B with 9.63% growth.

• Revenue (ttm): 20.05B CNY
• Revenue Growth: +17.16%
• P/S Ratio: 6.75
• Revenue / Employee: 1.59M CNY
• Employees: 12,575
• Market Cap: 148.25B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	18.68B	1.64B	9.63%
Dec 31, 2023	17.03B	1.77B	11.56%
Dec 31, 2022	15.27B	4.98B	48.38%
Dec 31, 2021	10.29B	4.68B	83.35%
Dec 31, 2020	5.61B	1.63B	40.88%